drugset / Trial / NCT06164431

Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273

NCT06164431

Phase 1 Completed 32 enrolled Guangdong Raynovent Biotech Co., Ltd
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to establish bioavailability of 2 treatments with ZSP1273: 200mg tablets and 200mg granules will be given to healthy Participants under fasting conditions. Bioavailability will be evaluated and verified on the basis of pharmacokinetic data.

Timeline

Start
2023-11-23
Primary completion
2023-12-15
Completion
2023-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Onradivir Small molecule 200 mg Oral

Indications

No indication recorded.